Comparable stake leader
PFIZER INC
SEC ownership of Allogene Therapeutics, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001737287.
Disclosed value leader
BlackRock, Inc.
Comparable rows
50/50
Latest evidence
30 Jun 2026
- Public ticker
- ALLO on Nasdaq
- Parsed ownership sources
-
13F, 13D/G, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
PFIZER INC
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
PFIZER INC
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001737287
- Issuer location
- South San Francisco, CA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Allogene Therapeutics, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
PFIZER INC
Disclosed value leader
BlackRock, Inc.
Comparable rows
50/50
Latest evidence
30 Jun 2026
13F
13D/G
3/4/5
Lead comparable stake: 9%
13D/G row: PFIZER INC
Showing 1-8 of 50 holder rows.
Quick read
PFIZER INC leads the comparable SEC ownership view at 9%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens PFIZER INC's linked filing trail.
Comparable ownership
Top 5
PFIZER INC
9%
Frazier Life Sciences Public Fund...
5.6%
STATE STREET CORP
5.5%
BlackRock, Inc.
5.3%
David D. Chang
4.9%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| PFIZER INC |
13F
13D/G
Company
|
9%
from 13D/G
|
$46,928,245
22,032,040 shares
|
— | 30 Jun 2026 |
| Frazier Life Sciences Public Fund, L.P. |
13D/G
|
5.6%
|
$37,528,939
19,445,046 shares
|
+$6,252,698 | 30 Jun 2026 |
| STATE STREET CORP |
13F
13D/G
Company · STATE STREET CORPORATION
|
5.5%
from 13D/G
|
$39,573,718
19,025,826 shares
|
— | 30 Jun 2026 |
| BlackRock, Inc. |
13F
13D/G
Company
|
5.3%
from 13D/G
|
$62,705,681
30,146,963 shares
|
— | 30 Jun 2026 |
| David D. Chang |
13D/G
3/4/5
David D. Chang, M.D., Ph.D. · President and CEO, Director
|
4.9%
|
$30,005,544
12,297,354 shares
|
+$478,560 | 31 Mar 2026 |
| FMR LLC |
13F
13D/G
Company
|
4.9%
from 13D/G
|
$24,978,809
12,009,043 shares
|
— | 30 Jun 2026 |
| Arie Belldegrun |
13D/G
3/4/5
Arie Belldegrun, M.D. · Director
|
3.9%
|
$26,268,416
13,610,578 shares
|
+$278,296 | 30 Jun 2026 |
| CITADEL ADVISORS LLC |
13F
13D/G
Company · Kenneth Griffin
|
2.8%
from 13D/G
|
$20,982,562
10,087,770 shares
|
— | 30 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$666,282.
Buys
$0
Insiders: 0
Sells
$666,282
Insiders: 6
Net
-$666,282
Shares: -355,265
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 355,265
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 29,697 | $0 | $62,958 | -$62,958 |
| 3-6 | 0 | 65,051 | $0 | $159,228 | -$159,228 |
| 6-9 | 0 | 222,987 | $0 | $396,969 | -$396,969 |
| 9-12 | 0 | 37,530 | $0 | $47,128 | -$47,128 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 23 reporting-owner rows connected to Allogene Therapeutics, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
23
Largest Forms 3/4/5 holder
TPG GP A, LLC
Net 12M change
-$666,284
Latest report
21 Aug 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| TPG GP A, LLC | 10%+ Owner | $59,413,042 | Mixed | 12 Jan 2022 | ||
| David D. Chang | President and CEO, Director | $15,472,516 | -$289,459 | -1.8% | Mixed | 16 Mar 2026 |
| Eric Thomas Schmidt | Chief Financial Officer | $6,396,524 | Mixed | 22 Mar 2023 | ||
| Arie Belldegrun | Director | $3,804,054 | Mixed | 02 Feb 2026 | ||
| Mr. Geoffrey Parker | Chief Financial Officer | $2,204,919 | -$88,411 | -3.9% | Filing P/S | 02 Feb 2026 |
| Alison Moore | Chief Technical Officer | $2,135,517 | Mixed | 22 Mar 2023 | ||
| Veer Bhavnagri | General Counsel | $1,765,122 | Mixed | 14 Mar 2023 | ||
| Rafael Amado | EVP of R&D | $1,720,353 | Mixed | 07 Oct 2022 | ||
| Earl Martin Douglas | SVP, General Counsel | $1,035,126 | -$103,262 | -9.1% | Filing P/S | 21 Aug 2026 |
| Zachary Roberts | President and CEO | $1,028,663 | -$104,169 | -9.2% | Filing P/S | 01 Jul 2026 |
| Joshua A. Kazam | Director | $972,249 | Mixed | 18 Jun 2026 | ||
| Franz B. Humer | Director | $664,215 | Filing P/S | 18 Jun 2026 | ||
| Benjamin Machinas Beneski | SVP, Chief Technical Officer | $488,345 | -$51,672 | -9.6% | Filing P/S | 31 Mar 2026 |
| Lillian Smith | VP, Corporate Counsel | $445,654 | Mixed | 01 Apr 2023 | ||
| Timothy L. Moore | Chief Technical Officer | $428,719 | Filing P/S | 03 Feb 2025 | ||
| Annie Yoshiyama | SVP, Finance | $287,634 | -$29,311 | -9.2% | Filing P/S | 21 Apr 2026 |
| Yinlin Jack Chen | SVP, Finance | $282,144 | Mixed | 10 Aug 2023 | ||
| Deborah M. Messemer | Director | $152,552 | Filing P/S | 18 Jun 2026 | ||
| Stephen Mayo | Director | Mixed | 18 Jun 2026 | |||
| Vicki L. Sato | Director | Mixed | 18 Jun 2026 |
Recent insider transactions for Allogene Therapeutics, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Earl Martin Douglas | ALLO | Common Stock | Sale | -5.73% | $62,958 | $2.12 | -29,697 | 488,267 | 21 Aug 2026 | Direct |
| Zachary Roberts | ALLO | Stock Option (Right to buy) | Award | 476,190 | 476,190 | 01 Jul 2026 | Direct | |||
| Zachary Roberts | ALLO | Restricted Stock Unit | Award | 134,530 | 134,530 | 01 Jul 2026 | Direct | |||
| Joshua A. Kazam | ALLO | Common Stock | Options Exercise | 13.6% | 47,700 | 398,463 | 18 Jun 2026 | Direct | ||
| Joshua A. Kazam | ALLO | Restricted Stock Unit | Award | 95,400 | 95,400 | 18 Jun 2026 | Direct | |||
| Joshua A. Kazam | ALLO | Restricted Stock Unit | Options Exercise | -100% | -47,700 | 0 | 18 Jun 2026 | Direct | ||
| Deborah M. Messemer | ALLO | Restricted Stock Unit | Award | 95,400 | 95,400 | 18 Jun 2026 | Direct | |||
| Stephen Mayo | ALLO | Stock Option (Right to buy) | Award | 144,400 | 144,400 | 18 Jun 2026 | Direct | |||
| Vicki L. Sato | ALLO | Restricted Stock Unit | Award | 95,400 | 95,400 | 18 Jun 2026 | Direct | |||
| Owen N. Witte | ALLO | Restricted Stock Unit | Award | 95,400 | 95,400 | 18 Jun 2026 | Direct | |||
| Franz B. Humer | ALLO | Restricted Stock Unit | Award | 95,400 | 95,400 | 18 Jun 2026 | Direct | |||
| Elizabeth A. Barrett | ALLO | Restricted Stock Unit | Award | 95,400 | 95,400 | 18 Jun 2026 | Direct | |||
| Annie Yoshiyama | ALLO | Common Stock | Sale | -7.15% | $22,144 | $2.31 | -9,586 | 124,517 | 21 Apr 2026 | Direct |
| Benjamin Machinas Beneski | ALLO | Common Stock | Sale | -1.45% | $7,168 | $2.50 | -2,867 | 195,338 | 31 Mar 2026 | Direct |
| Benjamin Machinas Beneski | ALLO | Common Stock | Sale | -2.38% | $11,942 | $2.47 | -4,835 | 198,205 | 16 Mar 2026 | Direct |
| David D. Chang | ALLO | Common Stock | Sale | -0.92% | $117,975 | $2.47 | -47,763 | 5,150,599 | 16 Mar 2026 | Direct |
| Benjamin Machinas Beneski | ALLO | Common Stock | Sale | -3.39% | $18,543 | $2.60 | -7,132 | 203,040 | 02 Mar 2026 | Direct |
| Benjamin Machinas Beneski | ALLO | Common Stock | Sale | -3.47% | $13,060 | $1.73 | -7,549 | 210,172 | 02 Feb 2026 | Direct |
| Benjamin Machinas Beneski | ALLO | Restricted Stock Unit | Award | 105,720 | 105,720 | 02 Feb 2026 | Direct | |||
| Benjamin Machinas Beneski | ALLO | Stock Option (Right to buy) | Award | 373,757 | 373,757 | 02 Feb 2026 | Direct | |||
| Annie Yoshiyama | ALLO | Common Stock | Sale | -3.1% | $7,167 | $1.72 | -4,167 | 130,322 | 02 Feb 2026 | Direct |
| Annie Yoshiyama | ALLO | Restricted Stock Unit | Award | 50,827 | 50,827 | 02 Feb 2026 | Direct | |||
| Annie Yoshiyama | ALLO | Stock Option (Right to buy) | Award | 179,691 | 179,691 | 02 Feb 2026 | Direct | |||
| Zachary Roberts | ALLO | Common Stock | Sale | -5.79% | $63,189 | $1.77 | -35,700 | 581,166 | 02 Feb 2026 | Direct |
| Zachary Roberts | ALLO | Restricted Stock Unit | Award | 203,307 | 203,307 | 02 Feb 2026 | Direct | |||
| Zachary Roberts | ALLO | Stock Option (Right to buy) | Award | 718,763 | 718,763 | 02 Feb 2026 | Direct | |||
| David D. Chang | ALLO | Common Stock | Sale | -1.8% | $171,484 | $1.80 | -95,269 | 5,185,862 | 02 Feb 2026 | Direct |
| David D. Chang | ALLO | Restricted Stock Unit | Award | 392,586 | 392,586 | 02 Feb 2026 | Direct | |||
| David D. Chang | ALLO | Stock Option (Right to buy) | Award | 1,387,931 | 1,387,931 | 02 Feb 2026 | Direct | |||
| Geoffrey M. Parker | ALLO | Common Stock | Sale | -1.88% | $42,242 | $1.76 | -24,001 | 1,252,795 | 02 Feb 2026 | Direct |
| Geoffrey M. Parker | ALLO | Restricted Stock Unit | Award | 152,480 | 152,480 | 02 Feb 2026 | Direct | |||
| Geoffrey M. Parker | ALLO | Stock Option (Right to buy) | Award | 539,072 | 539,072 | 02 Feb 2026 | Direct | |||
| Earl Martin Douglas | ALLO | Common Stock | Sale | -3.9% | $40,304 | $1.76 | -22,900 | 564,948 | 02 Feb 2026 | Direct |
| Earl Martin Douglas | ALLO | Restricted Stock Unit | Award | 152,480 | 152,480 | 02 Feb 2026 | Direct | |||
| Earl Martin Douglas | ALLO | Stock Option (Right to buy) | Award | 539,072 | 539,072 | 02 Feb 2026 | Direct | |||
| Arie Belldegrun | ALLO | Restricted Stock Unit | Award | 263,033 | 263,033 | 02 Feb 2026 | Direct | |||
| Arie Belldegrun | ALLO | Stock Option (Right to buy) | Award | 929,913 | 929,913 | 02 Feb 2026 | Direct | |||
| Zachary Roberts | ALLO | Common Stock | Sale | -4.08% | $40,980 | $1.56 | -26,269 | 616,866 | 21 Jan 2026 | Direct |
| Joshua A. Kazam | ALLO | Common Stock | Options Exercise | 15.7% | 47,700 | 350,763 | 18 Dec 2025 | Direct | ||
| Joshua A. Kazam | ALLO | Restricted Stock Unit | Options Exercise | -50% | -47,700 | 47,700 | 18 Dec 2025 | Direct | ||
| Benjamin Machinas Beneski | ALLO | Common Stock | Sale | -0.36% | $959 | $1.22 | -786 | 217,721 | 17 Nov 2025 | Direct |
| Geoffrey M. Parker | ALLO | Common Stock | Sale | -2.8% | $46,169 | $1.26 | -36,744 | 1,276,796 | 21 Oct 2025 | Direct |
* marks a reported price that did not pass the local price check.